ORKA
Oruka Therapeutics Inc.
$61.76
+$1.16(+1.91%)
75
Overall
60
Value
91
Tech
--
Quality
Market Cap
$3.00B
Volume
1.21M
52W Range
$5.49 - $53.56
Target Price
$63.00
Company Overview
| Mkt Cap | $3.00B | Price | $61.76 |
| Volume | 1.21M | Change | +1.91% |
| P/E Ratio | -562.3 | Open | $63.97 |
| Revenue | -- | Prev Close | $60.60 |
| Net Income | $-5.3M | 52W Range | $5.49 - $53.56 |
| Div Yield | N/A | Target | $63.00 |
| Overall | 75 | Value | 60 |
| Quality | -- | Technical | 91 |
No chart data available
About Oruka Therapeutics Inc.
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 1 trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.
Latest News
UBS Sticks to Its Buy Rating for Oruka Therapeutics (ORKA)
TipRanks Auto-Generated Intelligence Newsdesk•2 days ago
Analysts Are Bullish on These Healthcare Stocks: HeartFlow, Inc. (HTFL), Taysha Gene Therapies (TSHA)
Catie Powers•3 days ago
ORKA-001 Phase 1 Completion: What Oruka’s First-in-Human Milestone Means for Investors
TipRanks Clinical-Trials-Auto-Generated Newsdesk•7 days ago
Analysts Offer Insights on Healthcare Companies: Citius Oncology (CTOR) and Oruka Therapeutics (ORKA)
Catie Powers•a month ago
Analysts Offer Insights on Healthcare Companies: Denali Therapeutics (DNLI) and Oruka Therapeutics (ORKA)
Howard Kim•a month ago
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | ORKA | $61.76 | +1.9% | 1.21M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |